Drug Shortage Report for BIPAZEN

Last updated on 2023-06-21 History
Report ID 174021
Drug Identification Number 02513579
Brand name BIPAZEN
Common or Proper name Desmopressin Acetate Injection
Company Name KVR PHARMACEUTICALS INC.
Market Status MARKETED
Active Ingredient(s) DESMOPRESSIN ACETATE
Strength(s) 4MCG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size Cartons of 10 ampoules
ATC code H01BA
ATC description POSTERIOR PITUITARY LOBE HORMONES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2022-11-20
Actual start date 2022-11-20
Estimated end date 2023-06-21
Actual end date 2023-06-20
Shortage status Resolved
Updated date 2023-06-21
Company comments Back in stock. KVR has made the investment to produce three batches which have all been approved for release with the goal of carrying over a year of safety stock in the future.
Health Canada comments
Tier 3 Status No
Contact Address 21 PARR BLVD, UNIT 12
CALEDON, ONTARIO
CANADA L7E 4G3
Company contact information 1 877 302 2561 ext 101 info@kvrpharma.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v20 2023-06-21 English Compare
v19 2023-06-20 French Compare
v18 2023-06-20 English Compare
v17 2023-06-08 French Compare
v16 2023-06-08 English Compare
v15 2023-06-08 French Compare
v14 2023-06-08 English Compare
v13 2023-04-17 French Compare
v12 2023-04-17 English Compare
v11 2023-04-17 English Compare
v10 2023-03-14 French Compare
v9 2023-03-14 English Compare
v8 2023-02-16 French Compare
v7 2023-02-16 English Compare
v6 2022-12-15 French Compare
v5 2022-12-15 English Compare
v4 2022-11-21 English Compare
v3 2022-11-09 English Compare
v2 2022-11-09 French Compare
v1 2022-11-09 English Compare

Showing 1 to 20 of 20